12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SurVaxM: Phase I started

The institute began an open-label, U.S. Phase I trial to evaluate 4 vaccinations of subcutaneous SurVaxM given 2 weeks apart in 9 patients...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >